Equity Briefing: Healthcare Review For Friday July 6th, 2012
(Thomson Reuters ONE) -
Despite the fact that the U.S. economy posted its third consecutive month of
weak job growth and that some say the economic indicators are signaling a marked
deceleration of the U.S. economy, s number of healthcare stocks extended gains
on an otherwise slow Friday in the markets.
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) shares showed solid buying
today after plunging earlier in the week. On Tuesday the stock was down over
40% after the drug developer was notified by the FDA that data from the
continuing study of its Northera low-blood-pressure medication, the company's
lead drug candidate, is unlikely to provide enough evidence to support marketing
approval for the treatment. Share of the company are now up 33.78% to $1.21,
moving back above its key psychological resistance of $1 mark. Unfortunately,
however, it appears the stock move may have been fueled by stock promoters who
were compensated to push the stock higher.
XOMA Corporation(NASDAQ:XOMA) extended its gain for the fourth straight session
and made a new 52-week high of $4.13 this morning. The stock is now trading
higher by $4, extending its weekly to over 30%. On Jun 28, 2012, analyst at Roth
Capital had started coverage on the stock with a buy rating and set a price
target of $6. Last Wednesday, the started enrolling patients for two drug trials
-- a Phase III study in the eye disease non-infectious uveitis and a mid-stage
trial in erosive osteoarthritis in the hand.
Cadence Pharmaceuticals, Inc (NASDAQ:CADX) announced today that the company's
Chief Commercial Officer, Scott Byrd, will present the company's corporate
overview on Thursday, July 12, 2012 at 3:30pm Eastern Time during the 7th Annual
JMP Securities Healthcare Conference at the Peninsula New York Hotel in New York
City. Shares of the company are now up 8.17% to $3.97, extending its weekly gain
to over 32%.
Sucampo Pharmaceuticals, Inc (NASDAQ:SCMP) has received a final binding decision
on its claims in the dispute with its partner, Takeda Pharmaceutical Company
Limited. The International Court of Arbitration, International Chamber of
Commerce (ICC) did not agree with Sucampo's claims and did not award any
attorneys' fees or costs. Sucampo is disappointed with the ICC's decision.
Shares of SCMO slumped 25.90% to $5.15 on above average volume.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1625039]
Datum: 07.07.2012 - 01:14 Uhr
Sprache: Deutsch
News-ID 162988
Anzahl Zeichen: 3100
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 670 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing: Healthcare Review For Friday July 6th, 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
